NSABP FB-13

NSABP FB-13

An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive, HER2-Negative Primary Breast Cancer

Protocol Chair: Shannon Puhalla, MD

Protocol Officer: Thomas Julian, MD

Patient Population:
Newly diagnosed premenopausal patients with ER-positive, HER2-negative breast cancer that has not yet been treated

Target Accrual: 76 patients

Status: Not Recruiting

ClinicialTrials.gov Identifier: NCT03628066